Alnylam Pharmaceuticals Inc
ALNY
Market Cap$18.9B
Close$
$160.69
7.1% upside
Current Fair Value
7.1% upsideUndervalued by 7.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.90 Billion |
|---|---|
| Enterprise Value | $17.55 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.65 |
| Beta | 0.0 |
| Outstanding Shares | 126,491,778 |
| Avg 30 Day Volume | 486,644 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -56.9 |
|---|---|
| PEG | 91.59 |
| Price to Sales | 10.0 |
| Price to Book Ratio | -75.02 |
| Enterprise Value to Revenue | 8.76 |
| Enterprise Value to EBIT | -99.8 |
| Enterprise Value to Net Income | -53 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -4.66 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Alnylam Pharmaceuticals Inc
CEO: John Maraganore